C3N-01071
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 48.81861739
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.470
- OXIDATIVE_PHOSPHORYLATION+0.360
- DNA_REPAIR+0.260
- MYC_TARGETS_V1+0.240
- SPERMATOGENESIS+0.230
- E2F_TARGETS+0.200
- FATTY_ACID_METABOLISM+0.200
- ADIPOGENESIS+0.160
- CHOLESTEROL_HOMEOSTASIS+0.160
- COAGULATION+0.140
Top 10 suppressed
- NOTCH_SIGNALING-0.530
- HEDGEHOG_SIGNALING-0.500
- UV_RESPONSE_DN-0.390
- WNT_BETA_CATENIN_SIGNALING-0.390
- INTERFERON_ALPHA_RESPONSE-0.340
- TGF_BETA_SIGNALING-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- MITOTIC_SPINDLE-0.290
- APICAL_SURFACE-0.280
- INTERFERON_GAMMA_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-37-4135-01A-01R-1100-07 | — | cohortA1 | 0.829 |
| 2 | fa9f3cc6-06eb-4cfd-8f85-9d13df39d11e | — | — | 0.796 |
| 3 | TCGA-MZ-A7D7-01A-21R-A34R-07 | — | — | 0.788 |
| 4 | TCGA-A2-A3XV-01A-21R-A239-07 | — | B | 0.787 |
| 5 | TCGA-37-5819-01A-01R-1635-07 | — | cohortA3 | 0.786 |
| 6 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.786 |
| 7 | 0acddbbc-6b74-4fdd-903d-f5ec9bfd8514 | — | — | 0.786 |
| 8 | TCGA-64-1678-01A-01R-0946-07 | — | cohortA3 | 0.785 |
| 9 | TCGA-KU-A6H7-06A-21R-A31N-07 | — | — | 0.777 |
| 10 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| HYPOXIA | 0.050 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |